Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization
ID
Jørgensen, Astrid S.
(
Author
),
ID
Daugvilaite, Viktorija
(
Author
),
ID
De Filippo, Katia
(
Author
),
ID
Berg, Christian
(
Author
),
ID
Mavri, Maša
(
Author
),
ID
Benned-Jensen, Tau
(
Author
),
ID
Juzenaite, Goda
(
Author
),
ID
Hjortø, Gertrud Malene
(
Author
),
ID
Rankin, Sara
(
Author
),
ID
Våbenø, Jon
(
Author
),
ID
Rosenkilde, Mette Marie
(
Author
)
PDF - Presentation file,
Download
(2,73 MB)
MD5: 0758F6D03F982F6C02A34671669EFC83
URL - Source URL, Visit
https://www.nature.com/articles/s42003-021-02070-9
Image galllery
Abstract
Following the FDA-approval of the hematopoietic stem cell (HSC) mobilizer plerixafor, orally available and potent CXCR4 antagonists were pursued. One such proposition was AMD11070, which was orally active and had superior antagonism in vitro; however, it did not appear as effective for HSC mobilization in vivo. Here we show that while AMD11070 acts as a full antagonist, plerixafor acts biased by stimulating β-arrestin recruitment while fully antagonizing G protein. Consequently, while AMD11070 prevents the constitutive receptor internalization, plerixafor allows it and thereby decreases receptor expression. These findings are confirmed by the successful transfer of both ligands’ binding sites and action to the related CXCR3 receptor. In vivo, plerixafor exhibits superior HSC mobilization associated with a dramatic reversal of the CXCL12 gradient across the bone marrow endothelium, which is not seen for AMD11070. We propose that the biased action of plerixafor is central for its superior therapeutic effect in HSC mobilization.
Language:
English
Keywords:
stem cells
,
hematopoietic stem cells
,
GTP-binding proteins
,
molecular medicine
,
receptor pharmacology
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
VF - Veterinary Faculty
Publication status:
Published
Publication version:
Version of Record
Year:
2021
Number of pages:
12 str.
Numbering:
Vol. 4, art. 569
PID:
20.500.12556/RUL-137259
UDC:
577
ISSN on article:
2399-3642
DOI:
10.1038/s42003-021-02070-9
COBISS.SI-ID:
110393859
Publication date in RUL:
08.06.2022
Views:
2178
Downloads:
133
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Communications biology
Shortened title:
Commun. biolog.
Publisher:
Springer Nature
ISSN:
2399-3642
COBISS.SI-ID:
5134671
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:
12.05.2021
Projects
Funder:
Other - Other funder or multiple funders
Funding programme:
Lundbeck Foundation
Funder:
Other - Other funder or multiple funders
Funding programme:
University of Copenhagen, Faculty of Health and Medical Sciences
Funder:
ARRS - Slovenian Research Agency
Project number:
P4-0053
Name:
Endokrini, imunski in encimski odzivi pri zdravih in bolnih živalih
Funder:
ARRS - Slovenian Research Agency
Funding programme:
Young researchers
Funder:
Other - Other funder or multiple funders
Funding programme:
Novo Nordisk Foundation
Funder:
Other - Other funder or multiple funders
Funding programme:
AP Moller Foundation for Medical Research
Funder:
WT - Wellcome Trust
Project number:
201356/Z/16/Z
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back